US three-way oncology R&D (research and development) pact underway
This article was originally published in Clinica
Executive Summary
Three US public health agencies - the FDA, the Centers for Medicare & Medicaid Services (CMS) and the National Cancer Institute - have signed an agreement to collaborate on the validation of biomarkers that could be used to evaluate new cancer treatments.